A longevity‐specific bank of induced pluripotent stem cells from centenarians and their offspring

Todd W. Dowrey,Samuel F. Cranston,Nicholas Skvir,Yvonne Lok,Brian Gould,Bradley Petrowitz,Daniel Villar,Jidong Shan,Marianne James,Mark Dodge,Anna C. Belkina,Richard M. Giadone,Sofiya Milman,Paola Sebastiani,Thomas T. Perls,Stacy L. Andersen,George J. Murphy
DOI: https://doi.org/10.1111/acel.14351
IF: 11.005
2024-09-27
Aging Cell
Abstract:We collected centenarian and offspring peripheral blood samples connected to functional independence data. Isolated peripheral blood mononuclear cells (PBMCs) were used in targeted methylation arrays to fuel molecular aging clocks and establish biological age in these subjects, of which 20 were then successfully reprogrammed into high‐quality induced pluripotent stem cell (iPSC) lines. We report a one‐of‐a‐kind resource for studies of human longevity and resilience that can fuel the discovery and validation of novel therapeutics for aging‐related disease. Centenarians provide a unique lens through which to study longevity, healthy aging, and resiliency. Moreover, models of human aging and resilience to disease that allow for the testing of potential interventions are virtually non‐existent. We obtained and characterized over 96 centenarian and offspring peripheral blood samples including those connected to functional independence data highlighting resistance to disability and cognitive impairment. Targeted methylation arrays were used in molecular aging clocks to compare and contrast differences between biological and chronological age in these specialized subjects. Isolated peripheral blood mononuclear cells (PBMCs) from 20 of these subjects were then successfully reprogrammed into high‐quality induced pluripotent stem cell (iPSC) lines which were functionally characterized for pluripotency, genomic stability, and the ability to undergo directed differentiation. The result of this work is a one‐of‐a‐kind resource for studies of human longevity and resilience that can fuel the discovery and validation of novel therapeutics for aging‐related disease.
cell biology,geriatrics & gerontology
What problem does this paper attempt to address?